Form 13-F position report

TRAVERE THERAPEUTICS INC

Reported by Vestal Point Capital LP

TVTX CUSIP 89422G107 Manager CIK 0001974915

First reported at 600,000 shares this quarter.

New
% of reported 13F value 0.91% This manager · Q3 2026
Shares 600,000 Quarter-end amount reported
Reported value $35,328,000 Fair value at quarter end
Consecutive quarters held 1 Through Q3 2026

Reported position value by quarter

Reported position value by quarter

Each bar is a Form 13-F quarter-end snapshot. It does not show trades made within the quarter.

Reported position value by quarter
Date Holding Value
2025-06-30 5254000
2025-09-30 0
2026-09-30 35328000

Quarterly position history

How this manager's reported quarter-end position changed over time.

3 quarters
Quarterly reported position history for TRAVERE THERAPEUTICS INC held by Vestal Point Capital LP.
Quarter Activity Shares Change % of reported 13F Reported value Filed Source filing
Q3 2026 New 600,000 +600,000 (0.0%) 0.91% $35,328,000 2026-11-16
Q3 2025 Reduced 0 -355,000 (-100.0%) 0 $0 2025-11-14
Q2 2025 New 355,000 +355,000 (0.0%) 0.28% $5,254,000 2025-08-14

Who else reported the position

377 managers reported TRAVERE THERAPEUTICS INC for Q3 2026.

Managers reporting TRAVERE THERAPEUTICS INC in Q3 2026.
Manager Activity Shares Change % of reported 13F Reported value Tenure
JANUS HENDERSON GROUP PLC Added 11,891,480 +471,894 0.3% $700,058,180 1 qtr
BlackRock Inc Added 8,673,231 +652,568 < 0.01% $510,679,819 9 qtrs
FMR LLC Reduced 5,867,919 -1,228,695 0.01% $345,503,077 24 qtrs
Bank of America Corporation Added 5,824,254 +1,255,913 0.02% $342,932,099 24 qtrs
STATE STREET CORPORATION Added 4,387,309 +131,085 < 0.01% $258,324,754 23 qtrs
VANGUARD CAPITAL MANAGEMENT LLC Added 4,192,887 +84,193 < 0.01% $246,877,187 3 qtrs
PERCEPTIVE ADVISORS LLC Reduced 3,542,913 -209,661 3.63% $208,606,717 6 qtrs
VANGUARD PORTFOLIO MANAGEMENT LLC Added 3,040,158 +1,498,541 < 0.01% $179,004,503 3 qtrs
GEODE CAPITAL MANAGEMENT LLC Added 2,420,340 +48,453 < 0.01% $142,537,650 24 qtrs
ADAGE CAPITAL PARTNERS GP L L C Reduced 2,410,485 -158,871 0.2% $141,929,357 12 qtrs
Premium adds each manager's conviction percentile across reporting peers.
Filing details and methodology As reported
Report period
September 30, 2026
Filed
November 16, 2026
Filing type
13F-HR
Position type
COM

Voting authority reported

Sole
600,000
Shared
0
None
0

“None” means the manager reported no voting authority for those shares on non-routine matters. It does not disclose why and is not evidence of securities lending.

Form 13-F is a delayed quarter-end snapshot of disclosed long Section 13(f) securities. It can be filed up to 45 days after quarter end, excludes short positions and most non-U.S. securities, and does not reveal intra-quarter trading. For options, reported shares and value describe the underlying-share exposure; strike, expiry, premium, and written positions are not disclosed.